search

Active clinical trials for "Prostatic Hyperplasia"

Results 131-140 of 588

Observational Study to Compare Two Prostate Laser Enucleation Techniques in Terms of Urinary Incontinence...

Prostatic HyperplasiaBenign1 more

Benign prostatic hypertrophy or prostatic adenoma is a benign tumour that develops in the central part of the prostate. Prostatic adenoma can result in the progressive appearance of a difficulty in evacuating the bladder or frequent urges to urinate and other complications (lithiasis, haematuria, urinary retention, etc.). Surgery is indicated when medical treatment is no longer effective and in the case of complications. The endoscopic techniques for treating prostate adenoma, PLASMA and HOLEP, are recognised and recommended by the French Association of Urology and the European Association of Urology (EAU) as Gold Standard techniques in view of the good results reported in the literature, the low rate of complications compared to the other techniques, and the reduced hospitalisation rate. For prostate volumes less than 80cc, there is no difference between HOLEP and Bipolar Plasma Enucleation of the Prostate (BTUEP) in terms of International Prostate Symptom Score (IPSS), Qmax, and reoperation rate at 12 months. The surgeon's experience is the most important factor influencing the risk of complications for HOLEP. Urinary incontinence after HOLEP according to Houssin et al. is 14.5% at 3 months and 4.2% at 6 months, the risk factors identified were surgeon experience and the existence of diabetes. Comparative evaluation of the two techniques is less frequent, hence the interest of our prospective and multicentre study. In this study, the investigators hope to demonstrate a better outcome of the PLASMA technique in terms of post-operative residual urinary incontinence.

Not yet recruiting8 enrollment criteria

Prostatic Artery Embolization vs. Conventional Transurethral Prostatectomy in the Treatment of Benign...

Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a prevalent entity, affecting over 50% of men older than 60 years. The clinical picture of the disease includes lower urinary tract symptoms such as interrupted and weak urinary stream, nocturia, urgency and leaking and even sexual dysfunction in some individuals. Medical therapy is usually the first-line treatment. However, the efficacy of drugs like alpha-blockers is limited, and as disease progresses more invasive treatment options have to be taken into consideration. In cases with moderate to severe lower urinary tract symptoms (LUTS) transurethral resection of the prostate (TUR-P) is the standard treatment. TURP, however, is limited to prostates smaller than 60-80ml and the procedure is associated with a complication rate. The cumulative short-term morbidity rate is around 11% and the necessity for surgical revision is as high as 6%. Bleeding requiring transfusions and transurethral resection syndrome represent potentially serious threats to elderly and frail patients. Prostatic artery embolization (PAE) has been suggested as a minimal invasive alternative procedure, which can be performed in an outpatient setting with rapid recovery and low morbidity. The investigators hypothesize that PAE is non-inferior in the treatment of symptomatic BPH compared to conventional and established TUR-P.

Completed20 enrollment criteria

Clinical Trial to Evaluate the Efficacy and Safety of the Transarterial Supraselective Embolization...

Transurethral Resection of ProstateArtery Embolization2 more

The purpose of this study is to determine whether the transarterial supraselective embolization (TSE) is a technique as effective as transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).

Completed11 enrollment criteria

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients...

Benign Prostate Hyperplasia

The main objective of this study is to evaluate efficacy and safety of (Tamsulosin) HGP0412 and HIP1402 in patients with Benign Prostatic Hyperplasia

Completed3 enrollment criteria

Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)

Benign Prostatic HyperplasiaLower Urinary Tract Symptom

To evaluate the safety and efficacy of the Rezūm System and assess its effect on urinary symptoms secondary to benign prostatic hyperplasia (BPH).

Completed46 enrollment criteria

Evaluation of Finastride Effect in Different Dosage on the Amount of Perioperative Bleeding in Transurthral...

Benign Prostate Hyperplasia

Preoperative use of finastride will decrease the amount of perioperative blood loss during and after TURP The effect of finastride on decreasing the amount of perioperative blood loss during and after TURP is dose dependent Finastride will decrease microvascular density in prostate tissue and this effect is dose dependent

Completed6 enrollment criteria

Bioequivalence - Duodart Against Avodart & Omnic

Prostatic Hyperplasia

Open-label, randomized, single dose, two-treatment, two-way crossover study

Completed27 enrollment criteria

Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia...

Benign Prostatic Hypertrophy With Outflow ObstructionOveractive Detrusor

Persistent detrusor overactivity (DO) after transurethral prostatectomy results in symptomatic failure in more than one third of the patients. Storage symptoms are major complaints in the early postoperative period after Holmium Laser Enucleation of the Prostate (HoLEP). Levels of the urinary nerve growth factor (NGF), produced by bladder urothelium and smooth muscle, are increased in the patients with overactive bladder (OAB), and decreased after the OAB symptoms were improved. Also, urinary NGF levels are increased in patients with benign prostatic obstruction (BPO), but the changes of the NGF levels after relief of the BPO by the medical or surgical treatment have not been fully investigated. If the elevated urinary NGF levels are reduced after successful surgical treatment of BPO, measurement of urinary NGF could be a useful objective tool to assess the therapeutic outcomes of the operation. The aims of this study are to measure the urinary NGF levels in patients with BPO and to compare the results between the patients with detrusor overactivity (DO) and without detrusor overactivity (Non-DO), average 2 weeks before Holmium Laser Enucleation of the Prostate (HoLEP) procedure. After HoLEP, urinary NGF levels are rechecked at the periods of postoperative 3 months and 6 months, and compare changes between the two groups.

Completed9 enrollment criteria

Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures

Benign Prostatic Hypertrophy Requiring Surgical Intervention

To compare efficiency, in terms of tissue morcellation and removal time, of two commercially available FDA-approved morcellators: the VersaCut and the Piranha in subjects undergoing HoLEP procedure for benign prostatic hyperplasia (BPH).

Completed5 enrollment criteria

A Comparative Study of KSO-0400 in BPH Patients With LUTS

Benign Prostatic Hyperplasia (BPH)

The objective of this study is to evaluate the efficacy and safety of KSO-0400 compared to placebo for the treatment of LUTS caused by BPH.

Completed4 enrollment criteria
1...131415...59

Need Help? Contact our team!


We'll reach out to this number within 24 hrs